Clinical Trial Update: FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the FcRn antagonist efgartigimod for acute neuromyelitis optica spectrum disorder attacks is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 | Status: NOT_YET_RECRUITING